Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Tom DeBourcy
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q1 (7 quarters; questions recorded in 5).
- Questions
- 7on tracked calls
- Challenge rate
- 0%none of 7 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 5with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 7 of 7 questions from 2 companies
WSTWest Pharmaceutical Services4 questions · 4 reporting periods · 0 of 4 challenging
Calendar 2026 Q1
how you think about that business? I know you have the secrete platform and how you think about, I guess, adding to that portfolio
Show response
Eric outlined remaining portfolio: admin systems for hospitals, Crystal Zenith for high-end biologics/cell and gene therapy, SelfDose and other delivery devices with growing volumes. Views delivery devices as natural primary container extension from elastomers with continued investment planned.
Calendar 2025 Q4
refilling that demand. I wanted to see the opportunities you are seeing there,
Show response
Eric confirmed active reshoring conversations with customers building U.S. capacity. West's existing HVP assets can support with incremental labor and equipment rather than new facilities. CGM replacement business in several discussions for late 2026 ramp.
Calendar 2025 Q2
are most of the products in the portfolio validated across either multiple facilities and/or multiple geographies
Show response
Eric described the 5-center HVP network as well-positioned for regional production. Some products have single-site validation requiring transfers. Technology transfers take 12-18 months. Well-positioned overall, reflected in manageable tariff exposure.
Calendar 2025 Q1
your ability to capitalize on that opportunity and actually, you know, fill that that supply
Show response
Eric confirmed strong customer interest in filling CGM space with delivery device and drug handling contracts, noting seven-plus year typical agreements.
TECHBio-Techne3 questions · 2 reporting periods · 0 of 3 challenging
Calendar 2025 Q1
My question is just on the Diagnosis and Genomics organic growth. I know you have more difficult comps in the second half of the year
Show response
Kim attributed lower segment growth to order timing in diagnostic reagents and Asuragen, confirming no share loss or market slowdown. Year-to-date numbers healthy at high-single and low-double digits. Spatial Biology most impacted by NIH uncertainty but competitive positioning remains strong.
Calendar 2024 Q3
Just had a question related to your kind of directional guidance on Q2, and I guess kind of sequentially flat
Show response
Kim cited holiday calendar headwind (mid-week Christmas/New Year) and pharma stability without uptick yet. Cell and gene therapy expected to moderate from exceptional Q1.
would you expect that to be incrementally better versus last year?
Show response
Kim said budget flush looks less likely than more likely based on field feedback, though there's a thesis that pharma has been holding back CapEx and could flush if they see 2025 normalcy ahead.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| WST West Pharmaceutical Services | 4 | 0%none of 4 questions |
| TECH Bio-Techne | 3 | 0%none of 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 2 | 0%none of 2 questions | 1 |
| 2024 Q4 | No questions recorded | — | — |
| 2025 Q1 | 2 | 0%none of 2 questions | 2 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | No questions recorded | — | — |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
- 2024 Q32 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2024 Q4No questions recorded
- 2025 Q12 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q3No questions recorded
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Demand4
- Capital Allocation3
- Revenue Growth2
- Innovation & R&D1
- Supply Chain1
- Trade Tariffs1
- Guidance Reliability1
- Capex Investment1